What Is SS-31?
SS-31 is the research name for a synthetic four-amino-acid peptide better known clinically as:
Elamipretide
It has also appeared in research under names including:
MTP-131
Bendavia
and is now marketed as the FDA-approved drug:
Forzinity
SS-31 became popular in mitochondrial research because it does something unusual:
It selectively concentrates around the inner membrane of mitochondria.
Mitochondria are the structures inside cells responsible for producing much of the body’s usable cellular energy.
Elamipretide interacts particularly strongly with a mitochondrial membrane lipid called:
cardiolipin.
That interaction appears to help stabilize mitochondrial structure and improve the efficiency of several processes involved in cellular energy production.
Is SS-31 the Same as Elamipretide?
Yes.
In most scientific contexts:
SS-31 = Elamipretide
SS-31 was the experimental designation used during development.
Elamipretide is the generic pharmaceutical name.
And:
Forzinity
is the FDA-approved brand.
This is another compound in our library where a once-experimental “research peptide” eventually became an actual approved medicine.
Is SS-31 FDA Approved?
Yes — this changed in 2025.
On September 19, 2025, FDA granted accelerated approval to Forzinity (elamipretide).
It became:
the first FDA-approved treatment for Barth syndrome.
The approved indication is to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg.
This approval is narrow.
It does not mean SS-31 is FDA approved for:
- General fatigue
- Anti-aging
- Longevity
- Exercise performance
- Mitochondrial “optimization”
- Heart failure generally
- Alzheimer’s disease
- Parkinson’s disease
- Chronic fatigue syndrome
- Long COVID
- Weight loss
Those remain separate research questions.
Why Was the Approval “Accelerated”?
FDA used its:
Accelerated Approval pathway.
That allows approval for serious diseases based on an intermediate or surrogate endpoint reasonably likely to predict clinical benefit, while further confirmatory evidence is collected.
For Forzinity, approval was based on improvement in:
knee extensor muscle strength.
FDA states that continued approval may depend on confirmation of clinical benefit in additional trials.
So this is genuine FDA approval.
But it’s different from saying every long-term clinical question has already been answered.
What Is a Mitochondrion?
Mitochondria are sometimes called:
“the powerhouses of the cell.”
That’s simplified, but it’s basically true.
They convert energy from nutrients into:
ATP — adenosine triphosphate.
ATP is the immediate energy currency used for processes such as:
- Muscle contraction
- Nerve signaling
- Protein synthesis
- Cellular repair
- Heart function
- Maintaining ion gradients
- Basic cellular survival
Tissues with high energy demands—especially:
heart + skeletal muscle + brain
depend heavily on healthy mitochondrial function.
What Is Cardiolipin?
Cardiolipin is a specialized phospholipid found mainly in the:
inner mitochondrial membrane.
It helps organize the machinery responsible for energy production.
Cardiolipin contributes to:
- Mitochondrial membrane structure
- Cristae organization
- Electron transport-chain function
- Respiratory supercomplex organization
- ATP production
- Mitochondrial dynamics
- Cell-death signaling
When cardiolipin becomes abnormal, damaged, or improperly remodeled, mitochondrial performance can deteriorate.
This cardiolipin connection is central to understanding elamipretide.
How Does SS-31 Work?
The modern understanding is more sophisticated than:
“SS-31 is an antioxidant.”
Earlier descriptions often emphasized its ability to reduce:
reactive oxygen species — ROS.
That still matters.
But newer research suggests elamipretide works primarily by interacting with cardiolipin-rich areas of the inner mitochondrial membrane.
That interaction can influence:
membrane structure + electrostatic properties + respiratory-chain organization + protein assembly + mitochondrial efficiency.
In simplified terms:
SS-31 → inner mitochondrial membrane → cardiolipin → better organized mitochondrial machinery → potentially more efficient energy production.
That’s a much more accurate explanation than saying:
“SS-31 gives your mitochondria energy.”
What About ATP?
ATP production is one of the biggest reasons researchers became interested in SS-31.
Mitochondrial respiratory-chain proteins work together along the inner membrane to generate the electrochemical gradient used to produce ATP.
Cardiolipin helps these proteins organize properly.
Elamipretide appears to improve mitochondrial bioenergetics by stabilizing this membrane environment and supporting efficient respiratory-chain function.
So:
ATP production is absolutely a legitimate SS-31 research area.
But that doesn’t mean injecting SS-31 automatically makes every healthy person:
more energetic + stronger + faster + less tired.
Clinical outcomes depend on the underlying condition.
What About Oxidative Stress?
Mitochondria naturally produce reactive oxygen species during energy production.
At normal levels, ROS can participate in cellular signaling.
But excessive ROS can damage:
- Lipids
- Proteins
- DNA
- Mitochondrial membranes
Cardiolipin itself can be damaged by oxidation.
Elamipretide may help reduce this vicious cycle by stabilizing mitochondrial membranes and improving the efficiency of electron transport.
Modern research therefore views its oxidative-stress effects as part of a broader mitochondrial mechanism rather than simply acting as a free-floating antioxidant.
What Is Barth Syndrome?
Barth syndrome is a rare inherited mitochondrial disorder caused by mutations in the:
TAZ gene.
TAZ encodes a protein called:
tafazzin.
Tafazzin is important for proper cardiolipin remodeling.
When tafazzin doesn’t work correctly, cardiolipin becomes abnormal.
That can severely impair mitochondrial function.
Barth syndrome can involve:
- Cardiomyopathy
- Skeletal muscle weakness
- Exercise intolerance
- Growth delay
- Neutropenia
- Severe fatigue
- Mitochondrial dysfunction
Because the underlying disease directly involves cardiolipin, elamipretide was an especially logical drug to investigate.
Why Does Barth Syndrome Affect the Heart So Much?
The heart consumes enormous amounts of ATP.
It contracts:
every second of every day.
That makes cardiac muscle extraordinarily dependent on mitochondrial energy production.
Barth syndrome disrupts cardiolipin, which in turn disrupts:
mitochondrial structure + oxidative phosphorylation + ATP production.
That’s why cardiomyopathy is such an important feature of the disease.
What Did the Barth Syndrome Trials Show?
The development path wasn’t perfectly straightforward.
A Phase 2/3 randomized crossover trial included only 12 participants, which reflects how rare Barth syndrome is.
During the initial 12-week randomized periods:
neither primary endpoint was met.
Those endpoints included:
6-minute walk distance
and:
Barth Syndrome Symptom Assessment.
However, participants who continued into the longer open-label extension improved over time.
At 36 weeks, researchers reported an average improvement of about:
95.9 meters on the 6-minute walk test
along with improvement in symptom scores.
The eventual accelerated FDA approval relied on a broader body of evidence and an improvement in knee extensor muscle strength as the intermediate endpoint.
That’s a good example of rare-disease drug development being much more complicated than a simple:
“trial worked” / “trial failed.”
Does SS-31 Improve Muscle Strength?
For one specific population, there is now enough evidence for FDA to say:
yes.
Forzinity is approved specifically to improve muscle strength in qualifying patients with Barth syndrome.
But that finding does not automatically extend to:
- Healthy athletes
- Bodybuilders
- Older adults with normal mitochondria
- People wanting better gym performance
- General fatigue
- Sarcopenia from all causes
Those require their own evidence.
What About Exercise Endurance?
Barth syndrome frequently causes severe exercise intolerance because muscles cannot generate energy normally.
That’s why walking performance and muscle function were important clinical endpoints during development.
Other mitochondrial-disorder trials have also evaluated:
exercise capacity + muscle fatigue + oxygen utilization.
But human results outside Barth syndrome have been mixed.
So:
exercise physiology → major research area
while:
performance enhancer for healthy people → not established.
What About Primary Mitochondrial Myopathy?
This has been another major clinical research area.
Primary mitochondrial myopathies are inherited diseases in which mitochondrial dysfunction causes prominent:
muscle weakness + fatigue + exercise intolerance.
Elamipretide was studied in the MMPOWER clinical program.
Some early trials generated encouraging signals.
However, the larger MMPOWER-3 Phase 3 program did not establish the kind of clear overall efficacy needed for broad approval for primary mitochondrial myopathy.
A 2025 review notes that clinical results across primary mitochondrial myopathy and other disorders have been mixed despite compelling mechanistic rationale.
This is a recurring lesson with mitochondrial drugs:
improving mitochondria in a laboratory does not always translate into dramatic improvement in a complex human disease.
Why Would It Work Better in Barth Syndrome?
One possible reason is that Barth syndrome directly involves:
cardiolipin dysfunction.
And cardiolipin is precisely the mitochondrial structure elamipretide targets.
That creates a particularly tight biological match:
TAZ mutation → abnormal cardiolipin → mitochondrial dysfunction → cardiolipin-targeting drug.
A 2026 review specifically argues that this strong mechanistic alignment may help explain why elamipretide translated into clinically meaningful muscle effects in Barth syndrome while results were less convincing in heterogeneous diseases such as primary mitochondrial myopathy.
That is a very important point.
“Mitochondrial dysfunction” is not one disease.
What About Heart Failure?
Heart failure has been a major area of SS-31 research.
The reasoning is strong:
Failing heart muscle commonly shows abnormalities involving:
- Mitochondrial respiration
- ATP generation
- Oxidative stress
- Cardiolipin
- Mitochondrial structure
Preclinical studies produced promising cardiac effects.
Animal models have shown improvements in:
ventricular function + mitochondrial energetics + cardiac remodeling.
Human trials have also been conducted.
But clinical results have not established elamipretide as an approved general treatment for heart failure.
So:
heart failure research is legitimate.
“SS-31 repairs failing hearts” is not established.
What About Cardiomyopathy?
Again, we need to distinguish causes.
In:
Barth syndrome-associated cardiomyopathy
the cardiolipin connection is direct.
In ordinary cardiomyopathy caused by:
- Coronary disease
- Hypertension
- Genetic conditions
- Viral injury
- Other metabolic diseases
the pathophysiology may be very different.
Elamipretide isn’t approved as a universal cardiomyopathy medication.
What About Aging?
This is probably where the research-market hype starts.
Mitochondrial function changes with age.
Aging is associated with changes involving:
- Mitochondrial efficiency
- Oxidative stress
- Cardiolipin composition
- Energy production
- Muscle function
- Mitochondrial quality control
That makes elamipretide scientifically interesting to aging researchers.
Animal work has shown that SS-31 can improve aspects of mitochondrial function in aged tissues.
A 2025 review describes preclinical benefits across aging-related cardiac, skeletal muscle, and ocular models.
But:
SS-31 has not been proven to slow human aging or extend human lifespan.
That’s a very large leap beyond the evidence.
Is SS-31 a Longevity Peptide?
It is better described as:
a mitochondria-targeting peptide relevant to aging research.
Calling it a:
“longevity peptide”
can imply something we haven’t established:
that people taking it live longer or experience slower biological aging.
No such human evidence exists.
Does SS-31 Make Old Mitochondria Young Again?
This phrase is based loosely on some fascinating preclinical findings.
Experimental work has shown SS-31 can rapidly improve aspects of aged mitochondrial function—including resistance to stress and bioenergetic performance.
That’s scientifically exciting.
But:
restoring one mitochondrial measurement in old animal tissue
is not equivalent to:
reversing human aging.
We should keep the mechanism without turning it into a fountain-of-youth claim.
What About Fatigue?
This is a huge research-market search term.
Mitochondrial disorders can absolutely cause severe fatigue.
If cells cannot generate energy efficiently, people can experience:
- Muscle exhaustion
- Exercise intolerance
- Weakness
- Reduced endurance
So the connection between mitochondrial disease and fatigue is real.
But ordinary fatigue can arise from dozens of causes including:
sleep deprivation + anemia + thyroid disease + infection + depression + medications + nutrient deficiency + cardiopulmonary disease.
SS-31 has not been established as a general treatment for:
“low energy.”
What About Chronic Fatigue Syndrome / ME/CFS?
Mitochondrial metabolism has been studied in ME/CFS.
That naturally leads some people to wonder whether mitochondria-targeted medications such as SS-31 could help.
But there is not convincing clinical evidence establishing elamipretide as a treatment for:
ME/CFS.
This should remain a search/research category rather than a treatment claim.
What About Long COVID?
Similar reasoning.
Long COVID research includes abnormalities involving:
- Metabolism
- Mitochondrial function
- Immune signaling
- Exercise intolerance
- Fatigue
That makes mitochondria-targeted therapy scientifically interesting.
But elamipretide is not established or FDA approved as a Long COVID treatment.
What About Brain Fog?
Brain cells require substantial energy.
Mitochondrial dysfunction can affect neurological function.
That provides a biological reason to study mitochondrial therapeutics in cognition.
But there is no strong evidence that SS-31 reliably improves:
everyday brain fog in otherwise healthy people.
What About Alzheimer’s Disease?
Mitochondrial dysfunction and oxidative stress are heavily studied in Alzheimer’s disease.
Preclinical elamipretide research has therefore explored:
neurodegeneration + mitochondrial protection + oxidative injury.
Reviews continue to describe neurodegenerative disease as an area of potential mitochondrial-targeted therapy.
But SS-31 has not been established as a human Alzheimer’s treatment.
It should not be marketed as:
preventing dementia or restoring memory.
What About Parkinson’s Disease?
Same distinction.
Parkinson’s disease has strong links to:
mitochondrial dysfunction + oxidative stress + impaired mitochondrial quality control.
That makes SS-31 mechanistically relevant.
But mechanistic relevance is not clinical proof.
There is no FDA-approved elamipretide indication for Parkinson’s disease.
What About ALS?
Mitochondrial abnormalities have also been investigated in ALS.
But there is not strong human evidence showing SS-31 treats ALS or slows its progression.
This is a particularly important area where experimental mitochondrial biology should not be turned into unsupported therapeutic claims.
What About Eye Disease?
Elamipretide has actually had significant ophthalmology research.
Mitochondria are extremely important in retinal cells because vision requires substantial energy.
Clinical development has included diseases such as:
age-related macular degeneration.
The ReCLAIM program evaluated elamipretide in people with dry AMD and geographic atrophy.
Research has produced interesting signals, but elamipretide is not currently FDA approved for macular degeneration.
So eye health is a legitimate SS-31 research category.
What About Kidney Disease?
The kidneys are also metabolically demanding organs rich in mitochondria.
Preclinical research has evaluated SS-31 in:
- Acute kidney injury
- Chronic kidney disease
- Ischemia-reperfusion injury
- Metabolic kidney injury
Animal studies have generated encouraging findings.
But there is no established human indication for kidney disease.
Again:
kidney mitochondrial research → yes.
approved kidney therapy → no.
What About Ischemia-Reperfusion Injury?
This is one of the classic SS-31 research areas.
Ischemia means:
a tissue temporarily loses adequate blood flow.
Reperfusion occurs when blood flow returns.
Paradoxically, restoring oxygen can produce a burst of:
oxidative stress + mitochondrial injury + inflammation.
This happens in situations such as:
- Heart attack
- Stroke
- Transplantation
- Major surgery
Mitochondria-targeting antioxidants and membrane stabilizers such as elamipretide have therefore been studied extensively in ischemia-reperfusion models.
Preclinical evidence is substantial.
Human therapeutic success has been much harder to establish.
What About Muscle Loss & Sarcopenia?
Aging-related muscle weakness involves several factors:
- Reduced activity
- Motor-neuron changes
- Hormonal changes
- Protein metabolism
- Mitochondrial decline
Because SS-31 improves mitochondrial function in some aging animal models, researchers have studied it in the context of muscle aging.
But it is not established as a treatment for age-related:
sarcopenia.
It also does not directly function as an anabolic peptide.
Does SS-31 Build Muscle?
No evidence establishes that.
Its approved Barth syndrome indication is to improve muscle strength.
That doesn’t mean it increases muscle size or directly stimulates hypertrophy.
Better mitochondrial energy production can potentially allow muscle to function better without creating more muscle tissue.
So:
muscle function ≠ bodybuilding.
Does SS-31 Burn Fat?
No meaningful clinical evidence establishes SS-31 as a weight-loss or fat-burning compound.
Mitochondria are central to fat oxidation.
But the reasoning:
“mitochondria burn fuel, therefore SS-31 burns fat”
is far too simplistic.
Semaglutide, tirzepatide and retatrutide have actual large weight-loss trials.
SS-31 does not.
What About Insulin Resistance & Diabetes?
Mitochondrial metabolism is deeply involved in:
- Glucose oxidation
- Fatty-acid metabolism
- Insulin signaling
- Metabolic disease
Animal studies have explored elamipretide in metabolic dysfunction.
But SS-31 is not an established diabetes medication and should not be presented as a substitute for proven metabolic treatments.
What About Exercise Performance?
A healthy athlete already has functioning mitochondria.
Improving diseased mitochondria is not the same as supercharging normal ones.
There is no strong evidence showing SS-31 meaningfully improves:
- Running speed
- Strength
- VO2 max
- Athletic performance
- Muscle growth
in healthy athletes.
This is a common place where disease research gets stretched into performance marketing.
What About Recovery?
Mitochondrial energy production and oxidative stress influence cellular recovery.
So recovery is reasonable as a research topic.
But SS-31 has not been established to:
heal tendons + repair ligaments + speed workout recovery + eliminate soreness.
That’s very different from peptides such as BPC-157 or TB-500, where tissue-repair pathways are the primary research story.
SS-31 vs. MOTS-c
These two are constantly grouped together because both involve mitochondria.
But they’re very different.
SS-31 / Elamipretide
Synthetic tetrapeptide.
Targets:
inner mitochondrial membrane + cardiolipin.
Main research theme:
mitochondrial structural stability + bioenergetics.
MOTS-c
Naturally encoded mitochondrial-derived peptide.
Main research themes:
cellular signaling + AMPK + metabolism + exercise + metabolic adaptation.
SS-31 acts much more directly on mitochondrial membrane architecture.
MOTS-c acts more like a mitochondrial signaling molecule.
Neither one’s evidence should be transferred to the other.
SS-31 vs. NAD+
These are also very different.
NAD+
Is an essential cellular coenzyme involved in:
redox reactions + metabolism + DNA repair + signaling.
SS-31
Is a peptide targeting:
cardiolipin and the inner mitochondrial membrane.
Both are discussed around:
energy + aging + mitochondrial health.
But their mechanisms are not remotely interchangeable.
SS-31 vs. CoQ10
CoQ10 participates directly in the mitochondrial:
electron transport chain.
It carries electrons between respiratory complexes.
SS-31 instead appears to influence the structural membrane environment around those complexes.
So in simplified form:
CoQ10 → electron carrier
SS-31 → mitochondrial membrane/cardiolipin stabilizer.
That doesn’t mean combining them has proven synergy.
SS-31 vs. MitoQ
MitoQ is a mitochondria-targeted derivative of:
coenzyme Q10.
It was designed to concentrate antioxidant activity within mitochondria.
SS-31 is a peptide with a different mechanism centered heavily on:
cardiolipin + membrane organization + bioenergetics.
Both may influence oxidative stress.
But elamipretide is increasingly understood as much more than simply a mitochondrial antioxidant.
Evidence Snapshot
Defined Synthetic Peptide: Yes
Mitochondrial Targeting: Strong evidence
Cardiolipin Interaction: Strong evidence
Mitochondrial Bioenergetics Research: Extensive
Laboratory Research: Extensive
Animal Research: Extensive
Human Clinical Research: Yes
Barth Syndrome Human Trials: Yes
Barth Syndrome FDA Approval: Yes
FDA-Approved Brand: Forzinity
Approval Date: September 19, 2025
Approved Purpose: Improve muscle strength in Barth syndrome patients weighing ≥30 kg
Primary Mitochondrial Myopathy Research: Yes, mixed results
Heart-Failure Research: Yes, not an approved indication
Macular-Degeneration Research: Yes, not approved
Anti-Aging Evidence: Preclinical interest, not established clinically
Human Lifespan Extension: No evidence
Healthy-Person Energy Enhancement: Not established
Weight-Loss Evidence: Insufficient
Overall Evidence: One of the strongest and most clinically advanced mitochondria-targeting peptides, with FDA approval for a very specific cardiolipin-related mitochondrial disease.
What Do We Know?
We know SS-31 genuinely reaches and interacts with the inner mitochondrial membrane.
We know cardiolipin is central to:
mitochondrial structure + respiratory-chain organization + ATP production.
We know elamipretide can influence:
mitochondrial structure + respiratory efficiency + oxidative stress + bioenergetics.
And most importantly:
We now know enough clinically for FDA to approve elamipretide as Forzinity for improving muscle strength in qualifying patients with Barth syndrome.
That moves SS-31 far beyond the category of an obscure laboratory peptide.
What Don’t We Know?
We do not have strong evidence proving SS-31:
- Extends human lifespan
- Reverses human aging
- Makes healthy mitochondria “younger”
- Eliminates ordinary fatigue
- Treats chronic fatigue syndrome
- Treats Long COVID
- Treats fibromyalgia
- Treats Alzheimer’s disease
- Treats Parkinson’s disease
- Treats ALS
- Treats all mitochondrial diseases
- Treats heart failure generally
- Prevents heart attacks
- Treats kidney disease
- Treats macular degeneration
- Improves athletic performance in healthy people
- Builds muscle
- Burns fat
- Produces meaningful weight loss
- Treats diabetes
- Improves brain fog reliably
- Enhances cognition in healthy adults
- Improves longevity simply by raising ATP production
Those claims go well beyond the current clinical evidence.
What About Safety?
Now that elamipretide is an approved drug, we have considerably better human safety information than for most research peptides.
According to the FDA-approved Forzinity label, the most common adverse reactions include:
injection-site reactions.
The approved label also contains specific considerations for patients with severe renal impairment because systemic exposure can increase when kidney function is substantially reduced.
The existence of an FDA-approved pharmaceutical product does not mean every gray-market vial labeled “SS-31” has the same:
- Identity
- Purity
- Concentration
- Sterility
- Stability
- Manufacturing controls
This distinction is especially important now.
Research-Market SS-31 vs. Forzinity
This needs to be crystal clear.
Forzinity
is:
FDA-approved elamipretide + regulated manufacturing + defined formulation + FDA-reviewed labeling + clinical evidence.
A research vial labeled “SS-31”
is:
not automatically Forzinity.
The scientific evidence supporting elamipretide does not independently verify any third-party product.
Just like with pharmaceutical semaglutide or bremelanotide:
molecule evidence and product evidence are not the same thing.
Research & Regulatory Status
This profile needs an update compared with older peptide sites.
You will still find pages saying:
“SS-31 is experimental and not FDA approved.”
That information is now outdated.
FDA granted accelerated approval to:
Forzinity — elamipretide
on September 19, 2025 as the first treatment for Barth syndrome.
Its approved indication is specifically:
improving muscle strength in adult and pediatric Barth syndrome patients weighing at least 30 kg.
The approval was based on improvement in knee extensor muscle strength and remains subject to confirmatory clinical evidence under the accelerated approval framework.
All of the broader uses discussed in peptide and longevity communities remain unapproved unless separately established.
Your Pep Resource Takeaway
SS-31 has one of the most interesting development stories in the entire mitochondrial-peptide space.
The scientific logic starts at an extremely fundamental part of cellular biology:
cardiolipin → inner mitochondrial membrane → respiratory-chain organization → ATP production.
SS-31 travels to that membrane and interacts with cardiolipin, helping stabilize the environment where cellular energy is produced.
And unlike many “mitochondrial peptides,” this mechanism has now made the jump from:
cell studies → animal models → human trials → FDA-approved medicine.
In September 2025, elamipretide became Forzinity, the first FDA-approved treatment for Barth syndrome.
That’s significant.
But it does not validate the much larger list of claims now attached to SS-31 online:
more energy + no fatigue + better workouts + anti-aging + brain optimization + longevity + fat loss + heart repair + neuroprotection.
Barth syndrome is an unusually logical target because the disease itself directly damages cardiolipin metabolism, which is exactly where elamipretide acts.
That may help explain why one mitochondrial disease produced an approval while trials in broader, more heterogeneous conditions have produced mixed results.
So the accurate description in 2026 is:
SS-31 / elamipretide is a legitimate mitochondria-targeting peptide with strong mechanistic evidence and an FDA-approved use in Barth syndrome—but claims that it broadly “repairs mitochondria,” reverses aging, or boosts healthy-person energy remain far ahead of clinical evidence.
Research Areas / Search Keywords
SS-31, SS31, SS 31, elamipretide, elamipretide peptide, Forzinity, Forzinity elamipretide, MTP-131, MTP131, Bendavia, mitochondrial peptide, mitochondria peptide, mitochondrial health, mitochondrial function, mitochondrial dysfunction, dysfunctional mitochondria, cellular energy, energy production, cellular energy production, ATP, ATP production, adenosine triphosphate, bioenergetics, mitochondrial bioenergetics, oxidative phosphorylation, OXPHOS, electron transport chain, ETC, respiratory chain, mitochondrial respiration, inner mitochondrial membrane, IMM, mitochondrial membrane, mitochondrial cristae, cristae structure, cardiolipin, cardiolipin peptide, cardiolipin binding, cardiolipin stabilizer, mitochondrial cardiolipin, membrane stability, mitochondrial membrane potential, respiratory supercomplex, electron transport supercomplex, mitochondrial proteins, mitochondrial protein organization, reactive oxygen species, ROS, oxidative stress, mitochondrial oxidative stress, mitochondrial antioxidant research, free radicals, lipid peroxidation, mitochondrial damage, mitochondrial repair research, mitochondrial medicine, mitochondrial therapeutics, mitochondrial disease, mitochondrial disorder, primary mitochondrial disease, primary mitochondrial myopathy, PMM, mitochondrial myopathy, mitochondrial muscle weakness, exercise intolerance, muscle fatigue, muscle weakness, muscle energy, muscle function, muscle strength, Barth syndrome, Barth syndrome treatment, TAZ gene, TAZ mutation, tafazzin, tafazzin deficiency, cardiolipin remodeling, abnormal cardiolipin, Barth syndrome cardiomyopathy, pediatric cardiomyopathy, heart muscle disease, cardiomyopathy, heart failure research, cardiac mitochondria, heart mitochondria, cardiac energy, heart muscle energy, congestive heart failure research, HFrEF research, heart failure with reduced ejection fraction, left ventricular function, cardiac remodeling, ischemia, reperfusion, ischemia reperfusion injury, heart attack research, myocardial infarction research, stroke research, organ transplantation research, kidney research, kidney mitochondria, acute kidney injury research, chronic kidney disease research, renal ischemia research, brain mitochondria, neurological health, neuroprotection, neuroprotective peptide, neurodegeneration, Alzheimer’s research, dementia research, Parkinson’s research, ALS research, motor neuron disease research, cognitive decline, brain fog research, cognition research, mitochondrial brain health, eye health, retinal mitochondria, retina research, age-related macular degeneration, AMD, dry AMD, geographic atrophy, ReCLAIM trial, muscle aging, sarcopenia research, aging, healthy aging, aging mitochondria, mitochondrial aging, longevity research, anti-aging peptide, longevity peptide, biological aging, lifespan research, healthspan research, age-related mitochondrial decline, exercise, exercise endurance, endurance research, exercise performance, athletic performance research, workout energy, workout recovery research, recovery peptide, muscle recovery, chronic fatigue, fatigue research, low energy, tired all the time, unexplained fatigue, chronic fatigue syndrome, ME/CFS research, CFS research, Long COVID research, post-viral fatigue research, fibromyalgia research, metabolic health, glucose metabolism, insulin resistance research, diabetes research, metabolic syndrome, fatty acid oxidation, fat metabolism, weight loss research, fat burning research, mitochondria and weight loss, SS-31 weight loss, SS-31 energy, SS-31 anti-aging, SS-31 fatigue, SS-31 longevity, SS-31 mitochondria, elamipretide clinical trials, elamipretide FDA approval, SS-31 FDA approval, Forzinity FDA approval, Barth syndrome FDA treatment, accelerated approval, knee extensor strength, muscle strength, TAZPOWER trial, MMPOWER, MMPOWER-3, PROGRESS-HF, ReCLAIM, SS-31 vs MOTS-c, elamipretide vs MOTS-c, MOTS-c, SS-31 vs NAD+, NAD+, SS-31 vs CoQ10, CoQ10, SS-31 vs MitoQ, MitoQ, mitochondrial supplements research, research peptides, mitochondrial research peptides, gray market SS-31, research SS-31, SS-31 peptide vial, Forzinity vs SS-31.
Educational Disclaimer: This profile is provided for educational and research-information purposes only. It is not medical advice and does not provide dosing, administration, mitochondrial-disease treatment, anti-aging protocols, compounding, or purchasing recommendations. Elamipretide received FDA accelerated approval in September 2025 as Forzinity to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. That approval does not establish efficacy for general fatigue, aging, longevity, athletic performance, neurological disease, heart failure, or other unapproved uses, and it does not establish the quality or equivalence of research-market SS-31 products.